A patient that you have has been receiving albuterol (short-acting bronchodilator) pretty often due to difficulty breathing and wheezing. Which lab test are you concerned about?

A. A kink at some location in the chest tube: A kink in the tubing would obstruct fluid or air flow and prevent tidaling. If tidaling is present, it indicates that the tube is patent, so a kink is unlikely.

B. Normal and is to be expected: Tidaling in the water-seal chamber represents the rise and fall of fluid with inspiration and expiration, reflecting normal changes in intrathoracic pressure. It is an expected finding and indicates that the chest tube system is functioning properly.

C. The patient's lung has re-expanded and they are ready to have the chest tube removed: Lung re-expansion is assessed via imaging and clinical signs, not solely by tidaling. Tidaling alone does not indicate readiness for removal.

D. A problem within the chest tube unit: Tidaling indicates that the chest tube unit is working correctly. A problem would be suspected if there were no fluid movement or continuous bubbling without patient respiratory activity.

A. Potassium: Frequent use of albuterol, a beta-2 agonist, can cause a shift of potassium from the blood into the cells, leading to hypokalemia. Low potassium can result in muscle weakness, arrhythmias, and other cardiac complications, making it an important lab to monitor in this patient.

B. Sodium: Albuterol does not typically affect sodium levels. Monitoring sodium is not a primary concern in the context of frequent bronchodilator use unless there are other comorbidities affecting electrolyte balance.

C. White blood cells: WBC count is not directly affected by albuterol use. It is usually monitored for infection or inflammatory processes rather than medication side effects.

D. BUN and Creatinine: Renal function markers such as BUN and creatinine are not directly influenced by short-acting bronchodilator therapy. Monitoring these labs is not necessary solely due to albuterol administration.